Use of ErbB-2 Mimotopes for Breast Cancer Immunotherapy
Abstract
Recently a new drug (Herceptin) has been shown to be effective in the treatment of breast cancer, and has been approved for use. Herceptin is essentially a humanized mouse monoclonal antibody that binds to ErbB-2, a membrane growth factor receptor tyrosine kinase that is over expressed in 25-30% of patients with breast cancer. Herceptin prevents targeted cells from proliferating. Our goal is to induce the body to produce its own antibodies to ErbB-2, which hopefully like Herceptin will target breast cancer cells and then prevent them from growing. The specific purpose of this proposal was to test the use of phage particle mimetopes of ErbB-2, which when injected into mice, would induce the animals to make antibody against ErbB-2. Accordingly, we developed a phage selection protocol, and subsequently collected several M13 phage clones displaying high affinity binding to Herceptin. The selected clones were then used as immunogens to immunize Balb/c mice. At least two of these clones produced antibody responses that appear to be specific to ErbB-2 expressed on SKVO-3 cells. We have concluded that these mimotope phage clones are candidate immunogens for active immunotherapy trials in Balb/c mice with transplanted ErbB-2-positive tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA418637
Entities
People
- Allen J. Rosenspire
- Stamatina E. Ziemba
Organizations
- Wayne State University